Cargando…

Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia

Antipsychotic treatment resistance in schizophrenia remains a major issue in psychiatry. Nearly 30% of patients with schizophrenia do not respond to antipsychotic treatment, yet the underlying neurobiological causes are unknown. All effective antipsychotic medications are thought to achieve their ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amato, Davide, Kruyer, Anna, Samaha, Anne-Noël, Heinz, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557273/ https://www.ncbi.nlm.nih.gov/pubmed/31214054 http://dx.doi.org/10.3389/fpsyt.2019.00314

Ejemplares similares

S77. ROLE OF DOPAMINE AND GLUTAMATE TRANSPORTERS IN GENERATION OF ANTIPSYCHOTIC EFFICACY
por: Kruyer, Anna, et al.
Publicado: (2020)

Phospholipase C-β1 Hypofunction in the Pathogenesis of Schizophrenia
por: Kim, Seong-Wook, et al.
Publicado: (2015)

Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?
por: Bygrave, Alexei M., et al.
Publicado: (2019)

Reinforcement Learning and Dopamine in Schizophrenia: Dimensions of Symptoms or Specific Features of a Disease Group?
por: Deserno, Lorenz, et al.
Publicado: (2013)

Predictors for Antipsychotic Dosage Change in the First Year of Treatment in Schizophrenia Spectrum and Bipolar Disorders
por: Ringen, Petter Andreas, et al.
Publicado: (2019)

Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia
por: de Bartolomeis, Andrea, et al.
Publicado: (2020)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis
por: Polese, Daniela, et al.
Publicado: (2019)

Antipsychotics, Metabolic Adverse Effects, and Cognitive Function in Schizophrenia
por: MacKenzie, Nicole E., et al.
Publicado: (2018)

Influence of antipsychotics on metabolic syndrome risk in patients with schizophrenia
por: Koricanac, Aleksandra, et al.
Publicado: (2022)

Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
por: Rampino, Antonio, et al.
Publicado: (2019)

Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction
por: Nakao, Kazuhito, et al.
Publicado: (2019)

Readmission Rates of Patients with Schizophrenia Treated with Depot Antipsychotics versus Oral Antipsychotics in a Community Hospital
por: Espiridion, Eduardo D, et al.
Publicado: (2018)

Safety and Efficacy of High-Dose Vitamin B6 as an Adjunctive Treatment for Antipsychotic-Induced Hyperprolactinemia in Male Patients With Treatment-Resistant Schizophrenia
por: Zhuo, Chuanjun, et al.
Publicado: (2021)

Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
por: Yu, Zhi-min, et al.
Publicado: (2019)

The More, the Merrier…? Antipsychotic Polypharmacy Treatment Strategies in Schizophrenia From a Pharmacology Perspective
por: Hjorth, Stephan
Publicado: (2021)

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022)

Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
por: Sonnenschein, Susan F., et al.
Publicado: (2020)

Gyrification Connectomes in Unmedicated Patients With Schizophrenia and Following a Short Course of Antipsychotic Drug Treatment
por: Nelson, Eric A., et al.
Publicado: (2018)

Brain Networks Reveal the Effects of Antipsychotic Drugs on Schizophrenia Patients and Controls
por: Towlson, Emma K., et al.
Publicado: (2019)

Antipsychotics-induced improvement of cool executive function in individuals living with schizophrenia
por: Si, Yajing, et al.
Publicado: (2023)

The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS)
por: Kinon, Bruce J.
Publicado: (2019)

Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment?
por: Cheng, Zhang, et al.
Publicado: (2020)

Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia
por: Borovcanin, Milica M., et al.
Publicado: (2022)

NMDAR Hypofunction Animal Models of Schizophrenia
por: Lee, Gloria, et al.
Publicado: (2019)

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo
por: Kiss, Béla, et al.
Publicado: (2022)

Genetic and Metabolite Variability in One-Carbon Metabolism Applied to an Insulin Resistance Model in Patients With Schizophrenia Receiving Atypical Antipsychotics
por: Ward, Kristen M., et al.
Publicado: (2021)

Association of Serotonin(2c) Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia
por: Li, Jiang, et al.
Publicado: (2019)

Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis
por: Valencia Carlo, Yarmila Elena, et al.
Publicado: (2023)

The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies
por: Yang, Chengmin, et al.
Publicado: (2021)

Reduced Cell-Free Mitochondrial DNA Levels Were Induced by Antipsychotics Treatment in First-Episode Patients With Schizophrenia
por: Ouyang, Houxian, et al.
Publicado: (2021)

Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review
por: Coles, Alexandria S., et al.
Publicado: (2021)

Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia
por: Nicoletti, Ferdinando, et al.
Publicado: (2019)

Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report
por: Izuhara, Muneto, et al.
Publicado: (2018)

Prescription of Anticholinergic Drugs in Patients With Schizophrenia: Analysis of Antipsychotic Prescription Patterns and Hospital Characteristics
por: Hori, Hikaru, et al.
Publicado: (2022)

Magnetic resonance imaging of the dopamine system in schizophrenia – A scoping review
por: Schulz, Julia, et al.
Publicado: (2022)

Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis
por: Brandt, Lasse, et al.
Publicado: (2020)

Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia
por: Wu, Qiongqiong, et al.
Publicado: (2021)

Serum Epidermal Growth Factor is Low in Schizophrenia and Not Affected by Antipsychotics Alone or Combined With Electroconvulsive Therapy
por: Zhang, Xiaobin, et al.
Publicado: (2020)

Changes in Brain Structure, Function, and Network Properties in Patients With First-Episode Schizophrenia Treated With Antipsychotics
por: Yin, Ping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_skst11e40k5c0nqesfuanquuqh